NewAmsterdam Pharma (NAMS) Cash from Financing Activities (2023 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Cash from Financing Activities data on file, last reported at $11.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 69.73% year-over-year to $11.1 million; the trailing twelve-month figure through Mar 2026 stood at $34.1 million (down 92.72% YoY), and the FY2025 full-year result was $29.5 million, down 95.52% from the prior year.
• Cash from Financing Activities fell to $11.1 million in Q1 2026, from $13.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $456.6 million in Q4 2024 to a low of $58000.0 in Q3 2024.
• A 4-year average of $59.1 million and a median of $6.1 million in 2023 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 10058.62% in 2025, while the deepest fall reached 97.0% in 2025.
• Tracing NAMS's Cash from Financing Activities over 4 years: stood at $186000.0 in 2023, then soared by 245389.78% to $456.6 million in 2024, then plunged by 97.0% to $13.7 million in 2025, then slipped by 19.14% to $11.1 million in 2026.
• Business Quant data shows NAMS's Cash from Financing Activities at $11.1 million in Q1 2026, $13.7 million in Q4 2025, and $5.9 million in Q3 2025.